ABSTRACT
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Europea del Medicamento, hechos públicos en julio, septiembre y octubre de 2022 y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento.(AU)
The drugs assessed by the European Medicines Agency made public in July, September and October of 2022, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.(AU)
Subject(s)
Humans , Pharmaceutical Trade , Pharmaceutical Preparations , Legislation, DrugABSTRACT
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos de abril a junio 2022, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento. (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public from April to June of 2022, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product. (AU)
Subject(s)
Humans , Pharmaceutical Preparations , Equipment and Supplies , BudesonideABSTRACT
PURPOSE: To identify the evidence that supports the effect of interventions made by hospital pharmacists, individually or in collaboration with a multidisciplinary team, in terms of healthcare outcomes, a more effective utilization of resources and lower costs in older polymedicated inpatients. METHODS: We searched the following databases: MEDLINE, EMBASE and the Cochrane Library. We also conducted a hand search by checking the references cited in the primary studies and studies included in reviews identified during the process of research. Four review authors working by pairs searched for studies, extracted data, and drew up the results tables. RESULTS: Twenty-six studies were included in the review. In 13 of them pharmacists carried out their intervention exclusively while the patients were in hospital, whereas in 13 interventions were delivered during admission and after hospital discharge. Outcomes identified were mortality, length of stay, visits to the emergency department, readmissions and reported quality of life, among others. Pharmacist interventions were found to be beneficial in fifteen studies, specifically on hospital readmissions, visits to the emergency department and healthcare costs. CONCLUSION: There is no hard evidence demonstrating the effectiveness of hospital pharmacist interventions in older polymedicated patients. Mortality does not show as a relevant outcome. Other health care outcomes, such as hospital readmissions, visits to the emergency department and healthcare costs, seem to be more relevant and amenable to change. Interventions that include pharmacists in multidisciplinary geriatric teams seem to be more promising that isolated pharmacist interventions. Interventions prolonged after hospital discharge seem to be more appropriate that interventions delivered only during hospital admission. Better-designed studies should be conducted in the future to provide further insight into the effect of hospital pharmacist interventions.
Subject(s)
Inpatients , Pharmacists , Aged , Hospitals , Humans , Outcome Assessment, Health Care , Quality of LifeABSTRACT
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en octubre, noviembre y diciembre de 2019, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in October, November and December of 2019, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Subject(s)
Humans , Adolescent , Young Adult , Adult , Middle Aged , Aged , Drug Evaluation/methods , Health Personnel/standards , Clinical Trials as Topic , Treatment Outcome , Drug Evaluation/statistics & numerical data , International Agencies/standards , Medicine Package Inserts , Antibodies, Monoclonal , Ofloxacin , Ketamine , Glucagon , Imipenem , Central Nervous System Stimulants , Ebola VaccinesABSTRACT
Falls are a major public health concern in the older population, and certain medication classes are a significant risk factor for falls. However, knowledge is lacking among both physicians and older people, including caregivers, concerning the role of medication as a risk factor. In the present statement, the European Geriatric Medicine Society (EuGMS) Task and Finish group on fall-risk-increasing drugs (FRIDs), in collaboration with the EuGMS Special Interest group on Pharmacology and the European Union of Medical Specialists (UEMS) Geriatric Medicine Section, outlines its position regarding knowledge dissemination on medication-related falls in older people across Europe. The EuGMS Task and Finish group is developing educational materials to facilitate knowledge dissemination for healthcare professionals and older people. In addition, steps in primary prevention through judicious prescribing, deprescribing of FRIDs (withdrawal and dose reduction), and gaps in current research are outlined in this position paper.
Subject(s)
Accidental Falls/prevention & control , Analgesics, Opioid/adverse effects , Anticonvulsants/adverse effects , Geriatrics/methods , Psychotropic Drugs/adverse effects , Sodium Potassium Chloride Symporter Inhibitors/adverse effects , Accidental Falls/statistics & numerical data , Age Factors , Aged , Aged, 80 and over , Europe , European Union , Geriatrics/standards , Humans , Polypharmacy , Risk FactorsABSTRACT
Falls are a major public health concern in the older population, and certain medication classes are a significant risk factor for falls. However, knowledge is lacking among both physicians and older people, including caregivers, concerning the role of medication as a risk factor. In the present statement, the European Geriatric Medicine Society (EuGMS) Task and Finish group on fall-risk-increasing drugs (FRIDs), in collaboration with the EuGMS Special Interest group on Pharmacology and the European Union of Medical Specialists (UEMS) Geriatric Medicine Section, outlines its position regarding knowledge dissemination on medication-related falls in older people across Europe. The EuGMS Task and Finish group is developing educational materials to facilitate knowledge dissemination for healthcare professionals and older people. In addition, steps in primary prevention through judicious prescribing, deprescribing of FRIDs (withdrawal and dose reduction), and gaps in current research are outlined in this position paper.
ABSTRACT
Se presentan algunos aspectos clínicos de 216 pacientes con retraso mental severo y profundo. Hubo un predominio del sexo masculino (59,7 por ciento). La mayor parte de los casos tenían RM profundo (62,5 por ciento). Las causas prenatales de RM ocuparon el primer lugar en frecuencia. El 57,8 por ciento de los pacientes tenían epilépsia, parálisis cerebral infantil o ambas asociadas al RM. Otros déficit asociados como el visual, lenguaje o ambos afectó al 94,4 por ciento de los casos, y los trastornos de conducta al 34, 7 por ciento. Entre las malformaciones, las cardiovasculares fueron las más frecuentes (4,7 por ciento). Los resultados pedagógicos fueron satisfactorios en el 58 por ciento de los pacientes educables, y no satisfactorios en la totalidad de los entrenables. Los resultados obtenidos en la rehabilitación física fueron no satisfactorios en la mayoría de los pacientes
